LB Pharmaceuticals Inc

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing LB-102, an oral product candidate for schizophrenia, bipolar depression, and potentially other central nervous system disorders. The company has no approved products or commercial revenue yet and is building its business around advancing LB-102 through clinical development, regulatory review, and eventual commercialization if successful.

41.44

41.44

— LB Pharmaceuticals Inc
%
Lead product candidate100% Development of LB-102, the company's lead oral candidate for schizophrenia and bipolar depression.
Pipeline development0% Early-stage research and development work for additional product candidates and indications.
CMC and manufacturing support0% Formulation, chemistry/manufacturing/control, and clinical supply activities needed to support trials and future launch.

The company does not yet sell products commercially, so its near-term 'customers' are primarily clinical trial sites,...

  • Clinical trial ecosystemprimary

    Investigators, trial sites, CRO-like service providers, and CDMOs that support LB-102 development and supply.

  • Future patients with schizophreniaprimary

    Patients who may use LB-102 if it receives approval for acute schizophrenia and related indications.

  • Future patients with bipolar depressionsecondary

    Patients with bipolar depression who represent a second potential labeled use for LB-102.

  • Prescribers and payorsprimary

    Psychiatrists, health systems, and reimbursement bodies that will determine uptake and access after approval.

LB Pharmaceuticals is headquartered in the United States and its current operations are centered on U.S...

  • •Headquartered in the United States
  • •Clinical development and corporate operations are U.S.-based
  • •LB-102 royalty obligations apply to worldwide net sales
  • •No commercial revenue by country has been disclosed
  • •Future launch geography will depend on regulatory approvals

The company's strategy is to advance LB-102 through clinical development, secure regulatory approval, and ultimately...

01
Progress LB-102 clinical developmentshort-term

The company's value is concentrated in a single lead asset, so clinical success is the main driver of future viability.

02
Advance formulation and CMC readinessshort-term

Manufacturing and supply readiness are required for larger trials and any future commercial launch.

03
Maintain liquidity runwayshort-term

The company has no product revenue and expects continued losses, so cash management is essential to fund development.

04
Prepare for regulatory approval and commercializationmedium-term

Future value creation depends on moving from clinical-stage development to an approvable and reimbursable product.

LB Pharmaceuticals is a single-asset, clinical-stage company with no commercial revenue, so its business depends...

critical

Clinical development failure

LB-102 is still in clinical development, and negative efficacy or safety results would materially impair the company's value.

Scope
LB-102 Phase 2 and future trials
Materiality
high
high

Regulatory approval risk

Even if trials are positive, FDA or other regulators may require more data, delay approval, or impose restrictions.

Scope
Schizophrenia and bipolar depression indications
Materiality
high
high

Competitive pressure

Larger biopharma and biotech companies have greater resources and may develop better or faster CNS therapies.

Scope
Neuropsychiatry and CNS disorders
Materiality
high
high

Financing and dilution risk

The company has recurring losses and no product revenue, so it may need future capital raises to fund development.

Scope
Operating runway and future trials
Materiality
high
medium

Commercialization and reimbursement risk

If approved, uptake will depend on pricing, payer coverage, and physician acceptance in a crowded market.

Scope
Future launch of LB-102
Materiality
medium
Accrued research and development expenses
Can shift expense recognition between quarters
Stock-based compensation
Impacts operating loss and equity compensation disclosures
Marketable securities valuation
Affects liquidity presentation and interest income
Royalty obligations
Relevant if and when commercial sales begin

Lantern Pharma Inc.

LTRN · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

NRX Pharmaceuticals, Inc.

NRXP · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

LIPELLA PHARMACEUTICALS INC.

LIPO · Pharmaceutical Preparations

Semnur Pharmaceuticals, Inc.

SMNR · Pharmaceutical Preparations

: 28/04/2026